ADIM (4142) reported revenue of NT$634 million for Oct 2026, +6.7% year on year and +104.8% from the previous month. Revenue for Jan–Oct 2026 was NT$1.5 billion (+19.9% year on year).
Revenue for Oct 2026 was a record high (previous high: Oct 2025, NT$594 million). →
Year-on-year revenue growth: 4 months in a row. →
In Oct 2026, it ranked No. 13 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$634 million | +6.7% | +104.8% |
| Sep 2026 | NT$309.5 million | +90.1% | +216.1% |
| Aug 2026 | NT$97.9 million | +34.5% | -68.2% |
| Jul 2026 | NT$308.2 million | +28.6% | +727.7% |
| Jun 2026 | NT$37.2 million | -62.8% | +449.7% |
| May 2026 | NT$6.8 million | +51.9% | -70.2% |
| Apr 2026 | NT$22.7 million | +474.4% | -65.3% |
| Mar 2026 | NT$65.5 million | +2,102.7% | +1,019.6% |
| Feb 2026 | NT$5.8 million | -19.7% | -46.7% |
| Jan 2026 | NT$11 million | -82.2% | -46.7% |
| Dec 2025 | NT$20.6 million | -53.8% | -84.3% |
| Nov 2025 | NT$130.8 million | +537.9% | -78.0% |
| Oct 2025 | NT$594 million | +23.8% | +264.9% |
| Sep 2025 | NT$162.8 million | -52.3% | +123.6% |
| Aug 2025 | NT$72.8 million | -60.9% | -69.6% |
| Jul 2025 | NT$239.7 million | -33.6% | +139.2% |
| Jun 2025 | NT$100.2 million | +39.6% | +2,146.5% |
| May 2025 | NT$4.5 million | +223.0% | +12.6% |
| Apr 2025 | NT$4 million | -40.6% | +33.2% |
| Mar 2025 | NT$3 million | -91.1% | -59.2% |
| Feb 2025 | NT$7.3 million | -2.8% | -88.2% |
| Jan 2025 | NT$61.8 million | +1,972.7% | +38.8% |
| Dec 2024 | NT$44.6 million | — | +117.2% |
| Nov 2024 | NT$20.5 million | -86.7% | -95.7% |
| Oct 2024 | NT$480 million | -4.1% | +40.8% |
Jan–Oct 2026 cumulative: NT$1.5 billion (+19.9% YoY)
Other Biotech & Medical companies
Compare with peers: ADIM vs PEC / ADIM vs Lotus Pharm / ADIM vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16